High affinity (S/N was greater than 3 times the average S/N for the entire array) |
|
|
|
135 |
GalNAcα1-3Gal–Sp2 |
A disaccharide |
110.03 |
8 |
α-GalNAc–Sp2 |
α-GalNAc |
101.02 |
30 |
Galα1-4Galβ1-4Glcβ–Sp1 |
Pk; (ELβ Tri-) |
75.88 |
4 |
α-D-Gal–Sp2 |
Galα1- |
75.33 |
64 |
Galα1-3Galβ–Sp2 |
B disaccharide |
71.07 |
193 |
Galα1-3Galβ1-4Glcβ–Sp1 |
Galili Tri; (BL Tri-) |
62.93 |
9 |
β-GalNAc–Sp2 |
β-GalNAc |
58.25 |
31 |
Galα1-4Galβ1-4GlcNAcβ–Sp1 |
P1; (EIIβ) |
49.07 |
134 |
Galα1-2Galβ–Sp2 |
Galα1-2Gal |
46.78 |
167 |
Galα1-3Galβ1-4(Fucα1-3)GlcNAcβ–Sp2 |
αGalLex; (BII/Lex Tetra-) |
42.14 |
138 |
Galα1-3Galβ1-4GlcNAcβ–Sp2 |
Galα1-3′LacNAc; (BIIβ Tri-) |
36.69 |
65 |
Galβ1-2Galβ–Sp2 |
Galβ1-2Gal |
35.50 |
22 |
GalNAcβ1-4GlcNAcβ–Sp2 |
Lac-di-NAc |
34.51 |
82 |
GalNAcα1-3(Fucα1-2)Galβ–Sp7 |
Atri-long; (Ah) |
31.56 |
Medium affinity (S/N was greater than 2 times the average S/N for the entire array) |
|
|
|
172 |
GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ–Sp2 |
A type II; (AhII β) |
17.74 |
63 |
6-Su-GalNAcα–Sp2 |
α-GalNAc-6-sulphate |
16.54 |
67 |
Galβ1-4(6-O-Su)GlcNAcβ–Sp2 |
6′-O-su-LacNAc |
14.86 |
Low affinity (S/N was greater than the average S/N for the entire array) |
|
|
|
112 |
GalNAcβ1-4GlcNAcβ1-4Manα1-6(GalNAcβ1-4GlcNAcβ1- |
Bi-LDN (remodelled from human fibrinogen) |
12.91 |
|
4Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ-N–Sp |
|
|
203 |
GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAc–SP1.BT |
A-tetra type II; (AhII Tetra-) |
10.98 |
26 |
GalNAcβ1-4(Fucα1-3)GlcNAc–Sp1 |
Fucα1-3-Lac-di-NAc |
10.38 |
91 |
α-D-Gal-PAA–Sp1 |
α-D-galactose |
9.86 |
77 |
Galα1-3(Fucα1-2)Galβ–Sp7 |
Btri-long; (Bh) |
9.58 |
93 |
α-GalNAc-PAA–Sp1 |
α-GalNAc |
9.32 |
202 |
GalNAcα1-3(Fucα1-2)Galβ1-4Glc–SP1.BT |
A-tetra Lac; (AhL Tetra-) |
7.32 |